Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Gains from Investment Securities (2021 - 2025)

Core Scientific's Gains from Investment Securities history spans 3 years, with the latest figure at $5.0 million for Q1 2025.

  • For Q1 2025, Gains from Investment Securities rose 40.69% year-over-year to $5.0 million; the TTM value through Jun 2025 reached $6.6 million, up 47.16%, while the annual FY2024 figure was $6.0 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q1 2025 was $5.0 million at Core Scientific, up from $710000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $13.1 million in Q4 2022 and bottomed at -$10.0 million in Q2 2022.
  • The 3-year median for Gains from Investment Securities is $2.2 million (2024), against an average of $3.0 million.
  • The largest YoY upside for Gains from Investment Securities was 40.69% in 2025 against a maximum downside of 40.69% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $13.1 million in 2022, then crashed by 94.56% to $710000.0 in 2024, then soared by 604.23% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Gains from Investment Securities are $5.0 million (Q1 2025), $710000.0 (Q4 2024), and $862000.0 (Q3 2024).